Immuno-Oncology | Specialty

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

Weber Shares Insight on Future of Immunotherapy in Melanoma

January 26th 2018

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Dr. Bauml Discusses Liquid Biopsies in Lung Cancer

January 26th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Dr. Singh Discusses Immunotherapy Study in GIST

January 26th 2018

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Checkpoint Blockade Therapy Clears Safety Hurdle for Patients With HIV and Cancer

January 26th 2018

Although there has been reluctance among oncology researchers to administer immunotherapy to patients with HIV who develop cancer, early signals from a small clinical trial suggest that such a strategy may be safe in certain settings.

Moving Forward in Head and Neck Squamous Cell Cancer

January 25th 2018

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.

Dr. McKay Discusses Combinations in Renal Cell Carcinoma

January 24th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

January 23rd 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.

Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple Myeloma

January 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Dr. Garon on Sequencing of Agents for Advanced Lung Cancer

January 23rd 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

CMV Vaccine Falls Short in Phase III Trial

January 23rd 2018

ASP0113, an investigational DNA vaccine developed for cytomegalovirus-seropositive hematopoietic stem cell transplant patients, has failed to meet its primary and secondary endpoints.

Emerging Therapies for Follicular Lymphoma

January 23rd 2018

FL: Updated Data for Immunomodulatory Approaches

January 23rd 2018

Immunomodulatory Therapy for FL: The R-Squared Regimen

January 23rd 2018

Further Considerations for Relapsed/Refractory FL

January 23rd 2018

Treatment Approaches to Relapsed Refractory FL

January 23rd 2018

Optimizing Frontline Therapy and Maintenance in FL

January 23rd 2018

Frontline Treatment Approaches to Follicular Lymphoma

January 23rd 2018

FL: Monitoring to Initiate Therapy and Gauge Response

January 23rd 2018